Physician profile

Renee S Melfi

Pain Medicine (Physical Medicine & Rehabilitation) · East Syracuse, NY

NPI 1104925833

$1,918.59

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

See the full distribution for Pain Medicine (Physical Medicine & Rehabilitation)

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$64.31

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Merz North America, INC. $1,515.54 2019
Boston Scientific Corporation $197.73 2019-2021
Abbott Laboratories $114.61 2021-2023 Eterna, Proclaim, Octrode
Pfizer INC. $25.18 2019
Stimwave Technologies Incorporated $23.55 2021
Allergan, INC. $16.01 2019
Fidia Pharma USA INC. $13.89 2019
Almatica Pharma LLC $12.08 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Renee S Melfi

$1,918.59

in general payments reported 2019-2025

Years
2019-2023
Top company
Merz North America, INC.

https://glasscript.com/doctor/323129/renee-s-melfi

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.